5 Year Data Show Zeposia Treatment Was Associated with Reduced Brain Volume Loss In Patients with RMS

Results from the phase 3 DAYBREAK open-label extension trial for Zeposia (ozanimod; Bristol Myers Squibb, New York, NY) showed sustained reductions in brain volume loss and consistent safety profiles for up to 5 years of continuous treatment in individuals with relapsing forms of multiple sclerosis. Researchers who presented data from this study at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) also reported favorable results in brain volume loss for those who switched from interferon beta-1a to Zeposia.

Key findings include:

• Participants taking Zeposia for up to 5 years experienced low, stable rates of whole brain volume loss (annualized change -0.27% to -0.35%).
• Switching from interferon beta-1a to Zeposia reduced rates of whole brain and thalamic volume loss.
• High cortical grey matter volume reductions seen with interferon beta-1a were reversed after switching to Zeposia.
• Safety analysis of >8 years of data showed declining or stable rates of adverse events over time, with low rates of infections.

"These new analyses reinforce Zeposia's well-established efficacy and safety profile as an effective oral therapy, especially for newly diagnosed relapsing MS patients," said Jeffrey Cohen, MD of Cleveland Clinic. "The sustained reductions in brain volume loss over 5 years are particularly encouraging, given the importance of preserving brain tissue in MS."